The search for safe and effective CAR-T targets in AML
Florian Van Oers, Donovan Flumens, Simon Haentjens, Laurens Krekelbergh, Sébastien Anguille · 2026
Read The search for safe and effective CAR-T targets in AML by Florian Van Oers, Donovan Flumens, Simon Haentjens, Laurens Krekelbergh, Sébastien Anguille (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13526807.txt.
Description
Florian Van Oers and others systematically score, in a 2026 review, candidate targets for CAR-T cell therapy in acute myeloid leukemia. Engineered T cells transformed care for B-cell cancers, yet leukemia targets are scarce because most markers also appear on healthy blood stem cells, risking their destruction. Early trials against three popular targets gave few lasting remissions.
The team evaluated sixty-three leukemia-associated antigens for which CAR constructs exist. They used five criteria covering expression across patients, uniformity within a patient's disease, presence on leukemic stem cells, and sparing of normal stem and mature blood cells. A twenty-point framework elevated thirteen antigens as most promising, including ADGRE2, SIGLEC-6, and IL1RAP. Advantages, limits, and risk-reduction strategies are discussed for each, offering a prioritized map for next-generation designs.
Catalog record
| CREATOR | Florian Van Oers, Donovan Flumens, Simon Haentjens, Laurens Krekelbergh, Sébastien Anguille |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43515 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |